ArticleFrontiers in microbiology2025
Genotypic diversity and molecular characterization of DENV-2 in a Peruvian endemic region from 2016 to 2022: displacement of American/Asian genotype.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Epidemiological and Evolutionary Dynamics of Dengue Virus in Saudi Arabia: Insights from Three Decades of Molecular and Serological Surveillance.International journal of molecular sciences · 2026Pooled it
- Assessing the diagnostic performance of clinical, serological and molecular approaches to improve dengue case detection in the Peruvian Amazon.PLoS neglected tropical diseases · 2026Article
- Dengue Fever Diagnosis: Performance Characteristics of Current Tests and Emerging Detection Technologies.Molecular diagnosis & therapy · 2026Review
- Advances in molecular regulation and function of LDLR family in viral infection.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dengue is the most prevalent acute febrile disease with serious clinical consequences in the tropical and subtropical regions of Asia and America. In Peru, it represents a significant public health issue due to its hyperendemic nature, with serotype 2 (DENV-2) being the predominant serotype that leads to the most severe clinical manifestations of the disease. This study focuses on the molecular characterization and analysis of the intraserotypic diversity of DENV-2 circulating in the endemic region of Cajamarca. Methods: A total of 3,967 blood serum samples from patients with acute febrile illness (AFI) were analyzed between 2016 and 2022 to detect DENV and DENV-2 using real-time RT-PCR. The viral envelope (E) gene was then sequenced using the Sanger method. Finally, phylogenetic reconstruction was conducted using the maximum likelihood method. Results: A total of 32 complete sequences of the envelope gene were obtained, and the phylogenetic and characterization analyses of the amino acid sequences revealed that, during the period from 2016 to 2022, two DENV-2 genotypes circulated: the Am/As genotype and the cosmopolitan genotype in lineages 2 and C, respectively. Conclusion: Similarly, our findings showed that every studied outbreak was characterized by novel autochthonous variants of the Am/As genotype and by an imported variant of the cosmopolitan genotype; this demonstrates a temporal distribution of intraserotypic variability that indicates the displacement of the Am/As genotype around 2021 and the establishment of the cosmopolitan genotype. The need for ongoing genetic or genomic surveillance of the cosmopolitan virus arises in order to understand its distribution and diversification patterns in Peru.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.